Rapafusyn Pharmaceuticals, Inc.

Rapafusyn is a pharmaceutical company developing RapaGlues, a non-degrading molecular glue modality that brings the FKBP12 protein together with intracellular targets to inhibit protein-protein interactions, transcription factors, and other previously undruggable proteins. The company has a pipeline of drug candidates in development for oncology, immunology, inflammation, and acute kidney injury indications.